Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,208.12
+80.43 (+7.13%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal
↗
January 07, 2026
Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.
Via
Stocktwits
3 Drug Stocks to Buy at a Discount
↗
January 07, 2026
The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.
Via
The Motley Fool
The Valuation Wall: Nasdaq Momentum Stalls as the 'Great Rotation' of 2026 Takes Hold
January 07, 2026
The relentless surge that propelled the technology sector to historic heights throughout 2024 and 2025 has hit a significant roadblock in the opening week of 2026. As of January 7, 2026, the tech-heavy...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Eli Lilly Stock Rises After Hours On UBS ‘Buy’ Call Ahead Of Oral Obesity Pill Launch — GLP-1 Battle With Novo Heats Up
↗
January 06, 2026
Via
Stocktwits
The Great Rotation: How the 2026 Market Rally Outgrew the 'Magnificent Seven'
January 07, 2026
As the first week of trading in 2026 comes to a close, the S&P 500 has once again shattered records, crossing the 7,500 threshold with a momentum that feels fundamentally different from the...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
This Could Be Key to Pfizer's Turnaround in 2026
↗
January 07, 2026
Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.
Via
The Motley Fool
Topics
Intellectual Property
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition
↗
January 07, 2026
Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.
Via
Benzinga
Discover which S&P500 stocks are making waves on Wednesday.
↗
January 07, 2026
Via
Chartmill
The Alpha Renaissance: Goldman Sachs Reports Record Hedge Fund Gains in 2025
January 07, 2026
In a landmark year for active management, Goldman Sachs (NYSE: GS) has released its comprehensive 2025 year-end report, revealing that the hedge fund industry staged a dramatic comeback, delivering...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Why Did Eli Lilly Shares Surge Today? Key Factors
↗
January 07, 2026
Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.
Via
Talk Markets
Eli Lilly (LLY) Stock Is Up, What You Need To Know
January 07, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in...
Via
StockStory
Topics
Artificial Intelligence
My Top 5 Stocks to Buy in Early 2026
↗
January 07, 2026
These companies are leaders in their fields.
Via
The Motley Fool
Topics
Artificial Intelligence
Ventyx (VTYX) Shares Soar 62.5% Overnight, Here's What's Going On With This Trending Stock
↗
January 06, 2026
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.
Via
Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
↗
January 06, 2026
Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.
Via
The Motley Fool
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?
↗
January 06, 2026
Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?
Via
The Motley Fool
Topics
Intellectual Property
Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover
↗
January 06, 2026
Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.
Via
Investor's Business Daily
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
January 06, 2026
As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...
Via
MarketMinute
Topics
Economy
S&P 500 Shatters Records: Index Crosses 6,944 as Tech Giants and Healthcare Titans Lead the Charge
January 06, 2026
The S&P 500 reached a historic milestone on January 6, 2026, closing at a new all-time high of 6,944.82. This 0.6% gain on the first full trading week of the year signals a powerful continuation of the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout
↗
January 06, 2026
A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter.
Via
Stocktwits
Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI
↗
January 06, 2026
Under the deal, Nimbus is eligible to receive up to $1.3 billion.
Via
Stocktwits
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
January 06, 2026
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
January 06, 2026
As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
↗
January 06, 2026
Eli Lilly offers investors safety and growth.
Via
The Motley Fool
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss
↗
January 06, 2026
Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.
Via
Investor's Business Daily
Motley Fool Money: Stock Market Naughty and Nice List
↗
January 06, 2026
There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown?
↗
January 06, 2026
Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.
Via
Stocktwits
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List
↗
January 05, 2026
The development comes as attention remains on Hims’ longer-term business expansion initiatives.
Via
Stocktwits
2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore
January 05, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
Prediction: The S&P 500 $1 Trillion Club Will Double Between 2026 and 2030
↗
January 05, 2026
Several companies could see massive gains by 2030 to join the vaunted club.
Via
The Motley Fool
Topics
Stocks
The 2026 Blueprint: Five Core Stocks to Anchor Your Portfolio in a Year of AI Realization
January 05, 2026
As we cross the threshold into 2026, the financial markets have entered a sophisticated new phase. The "AI Gold Rush" of 2024 and 2025 has matured into what analysts are calling the "Era of AI...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.